Esophageal Cancer and Chronic Heartburn Market
Lucid Diagnostics sized the esophageal cancer and chronic heartburn market and highlighted its diagnostic technology related to this.
Lucid Diagnostics is a commercial-stage medical diagnostic technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and esophageal cancer, specifically highly lethal esophageal adenocarcinoma (EAC).
A company said that about 20,000 U.S. patients with GERD are expected to be diagnosed with CAE in 2023 and about 16,000 will die from it.
More than 80% of patients with CAE will die within five years of diagnosis, making it the second most lethal cancer in the United States.
The incidence of CAE in the United States has increased 500% over the past four decades, while the incidence of other common cancers has decreased or remained stable.
In almost all cases, CAE progresses silently until it manifests with new symptoms of advanced disease.
Esophageal cancer
ESCC is almost always invasive at the time of diagnosis and, unlike other common cancers, mortality rates are high even in the early stages.
Lucid Diagnostics believes that its flagship product, the EsoGuard esophageal DNA test, performed from samples collected with the EsoCheck esophageal cell collection device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent deaths from esophageal adenocarcinoma by early detection of esophageal precancer in at-risk patients with gastroesophageal reflux disease.
